



Atty. Dkt. No. 038602/0104

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: **Douglas CLARY**

Title: ***Methods Of Evaluating Specific Cellular Functions Of Receptor Protein Tyrosine Kinases In A Ligand Independent Manner***

Appl. No.: **09/057,150**

Filing Date: **April 7, 1998**

Examiner: **Nirmal Basi**

Art Unit: **1646**

#23
BJS
1/31/02

TECH CENTER 1600/2900

JAN 17 2002

RECEIVED

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

RELEVANCE OF EACH DOCUMENT


All of the documents are in English. Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Date January 14, 2002

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5143
Telephone: (202) 672-5475
Facsimile: (202) 672-5399

Respectfully submitted,

By 

Beth A. Burrous
Attorney for Applicant
Registration No. 35,087

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 038602/0104		SERIAL NO. 09/057,150	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Douglas CLARY			
				FILING DATE April 7, 1998		GROUP ART UNIT 1646	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A1	6,235,769	May 22, 2001	CLARY	514	418,419	
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	A2	Takahashi, "The GDNF/RET Signaling Pathway and Human Diseases", <i>Cytokine and Growth Factor Reviews</i> ; 12, pgs. 361-373, (2001)					
	A3	Oncogenes and Proto-Oncogenes online at http://www.intouchline.com/cancergenetics/onco.htm .					
	A4	The Dictionary of Cell and Molecular Biology – Online at http://www.mblab.gla.ac.uk/~julian/dict2.cgi?5399					
	A5	The Dictionary of Cell and Molecular Biology – Online at http://www.mblab.gla.ac.uk/~julian/dict2.cgi?4641					
	A6	Durbec, et al., "GDNF Signalling Through The Ret Receptor Tyrosine Kinase", <i>Nature</i> , Vol. 381, pgs. 789-793, (1996)					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							

[illegible]

002.693068